Joy Bessenger
Director of Finance/CFO at TRELLUS HEALTH PLC
Profile
Joy Bessenger is currently the Chief Financial Officer at Trellus Health Plc since 2023.
Prior to this, she worked as the Senior Vice President-Corporate Strategy at IMV, Inc. from 2021 to 2022.
Before that, she was the Director-Investor Relations at deCODE genetics, Inc. Ms. Bessenger completed her undergraduate degree at the University of South Florida.
Joy Bessenger active positions
| Companies | Position | Start |
|---|---|---|
| TRELLUS HEALTH PLC | Director of Finance/CFO | 18/09/2023 |
Former positions of Joy Bessenger
| Companies | Position | End |
|---|---|---|
| IMV INC. | Investor Relations Contact | 11/06/2022 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Public Communications Contact | - |
Training of Joy Bessenger
| University of South Florida | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| IMV INC. | Health Technology |
| TRELLUS HEALTH PLC | Technology Services |
| Private companies | 1 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
- Stock Market
- Insiders
- Joy Bessenger